by Admin | Jun 19, 2020 | Portfolio News
After teaming up with GlaxoSmithKline and Dynavax early on in the pandemic, Chinese biotech Clover Biopharmaceuticals has started trials of its COVID-19 vaccine and expects data in August. The company said the first participants have been dosed in its first clinical...
by Admin | Jun 7, 2020 | Portfolio News
June 07, 2020 09:00 PM Eastern Daylight Time BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24...
by Admin | May 18, 2020 | Portfolio News
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s portfolio, which is composed of the latest advances in...
by Admin | May 18, 2020 | Portfolio News
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a company singularly dedicated to addressing unsolved problems in stroke, today announced that Daniel Davis has been appointed as the company’s Chief Operating Officer. Mr. Davis will oversee the...
by Admin | May 11, 2020 | Portfolio News
Grant McFadden has spent over two decades studying the myxoma virus. The ASU virologist grew interested in the myxoma virus because it is extremely deadly in European rabbits but virtually harmless in non-rabbit hosts — including humans. He wanted to figure out why....
by Admin | Apr 27, 2020 | Portfolio News
CEPI to provide initial US$3.5m to Clover Biopharmaceuticals Australia, the wholly-owned subsidiary of Sichuan Clover Biopharmaceuticals, Inc (China) to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in...